Article
Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response.
PloS one - 1 Jan 2017
Asselah Tarik, Moreno Christophe, Sarrazin Christoph, Gschwantler Michael, Foster Graham R, Craxí Antonio, Buggisch Peter, Sanai Faisal, Bicer Ceyhun, Lenz Oliver, Van Dooren Gino, Nalpas Catherine, Lonjon-Domanec Isabelle, Schlag Michael, Buti Maria
Abstract excerpt
BACKGROUND: HCV GT4 accounts for up to 20% of HCV infections worldwide. Simeprevir, given for 12 weeks as part of a 24- or 48-week combination regimen with PR is approved for the treatment of chronic HCV GT4 infection. Primary study objectives were assessment of efficacy and safety of simeprevir plus PR in treatment-naïve patients with HCV GT4 treated for 12 weeks. Primary efficacy outcome was sustained virologic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.